The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Quinn T. Ostrom, Haley Gittleman, P Farah et al. · Neuro-Oncology · 2013 · 12.1K citations · Full text

Medicine, Neurology, Oncology +14

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations

Medicine, Immunology, Oncology +17